melphalan and Hyperplasia

We report a case of 77-year-old woman who presented with lumbago and hypercalcemia. Multiple myeloma (MM) was first diagnosed by serum protein electrophoresis and bone marrow aspiration, but intact parathyroid hormone (intactPTH) was also found to be high in the presence of persistent hypercalcemia with anorexia and nausea. After lowering serum calcium with bisphosphonate administration, parathyroidectomy was performed. Upon histologic examination, the tumor was determined to be parathyroidal chief-cell hyperplasia and the patient was treated with melphalan and prednisolone. The relationship between MM and primary hyperparathyroidism (I degree HPT) remains unknown. Although the co-existence of MM and I degree HPT was reported in 12 reports from various parts of the world, there was only 1 report in Japan. The present case is an example of successful treatment for a complicated disorder, and suggests that patients suffering from bone pain or hypercalcemia need to be examined both endocrinologically and hematologically.

Topics: Aged; Antineoplastic Agents; Female; Humans; Hypercalcemia; Hyperparathyroidism; Hyperplasia; Low Back Pain; Melphalan; Multiple Myeloma; Osteoporosis; Parathyroid Glands; Prednisolone

Melphalan (L-phenylalanine mustard), a cytostatic drug used in treatment of human breast cancer, was injected into mice bearing preneoplastic hyperplastic alveolar nodule mammary outgrowth line D2. Melphalan, doses of either 2.5 or 5.0 mg/kg, markedly enhanced tumor formation in its mammary nodule outgrowth line. Samples of nodule outgrowths in untreated mice produced 13% tumors by 9 months after transplantation, whereas nodule outgrowths in melphalan-treated mice produced 57 and 85% mammary tumors in the lower and higher dose groups, respectively.

Topics: Animals; Carcinogens; Female; Humans; Hyperplasia; Mammary Neoplasms, Experimental; Melphalan; Mice; Mice, Inbred BALB C; Precancerous Conditions; Stimulation, Chemical

A patient suffering from multiple myeloma developed pulmonary fibrosis, of a type known to be associated wtih busulphan, whilst being treated with Melphalan. The possible role of Melphalan as the causative agent is discussed. Reference is made to other possible aetiological agents and the reasons for their exclusion are discussed.

Topics: Autopsy; Bronchi; Humans; Hyperplasia; Lung; Male; Melphalan; Middle Aged; Multiple Myeloma; Pulmonary Alveoli; Pulmonary Fibrosis

Topics: Antineoplastic Agents; Aziridines; Breast Neoplasms; Cell Nucleus; Coloring Agents; Cyclophosphamide; Female; Hodgkin Disease; Humans; Hyperplasia; Hypertrophy; Mathematics; Melphalan; Ovarian Neoplasms; Pathology; Staining and Labeling; Thiotepa; Triethylenemelamine; Uterine Neoplasms; Vaginal Smears